{"brief_title": "Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy", "brief_summary": "Purpose of Phase II study for B-cell lymphoma using PS341: Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.", "detailed_description": "Patients were stratified, based on preclinical data, into arm A (mantle-cell lymphoma) or arm B (other B-cell lymphomas) without limitation in number of prior therapies. Bortezomib was administered as an intravenous push (1.5 mg/m2) on days 1, 4, 8, and 11 every 21 days for a maximum of six cycles.", "condition": ["Lymphoma, B-Cell"], "intervention_type": ["Drug"], "intervention_name": ["PS341 (Bortezomib)"], "description": ["1.5 mg/m2 intravenous (IV) bolus push over 3 to 5 seconds on days 1, 4, 8, and 11, followed by a 10-day rest for a 21-day cycle."], "arm_group_label": ["Arm A (mantle-cell lymphoma)", "Arm B (other B-cell lymphomas)"], "other_name": ["Velcade", "LPD-341", "MLN341", "PS-341"], "criteria": "INCLUSION: - Relapsed or Refractory B cell lymphoma. - Zubrod status </= 3. - Measurable disease. - No anti-cancer treatment within past 3 weeks. - ANC >= 1500/uL, Plt >/= 50,000, Bilirubin <2 mg/dL, SGPT <2.5xULN, creatinine <2. Patients with ANC>/1000, PLT>/30000 will be eligible if due to massive splenomegaly and/or BM involvement. - HIV negative. - No active CNS lymphoma. - No serious intercurrent illness, active infections or cancer except basal cell carcinoma of the skin or in situ cervical carcinoma. - Not eligible for treatment of a higher priority. Patients may be entered before BMT. - No pregnancy & age bearing females must be practicing adequate contraception. - Age > 16. EXCLUSION: - Patients with platelets <30x10(9)/L within 14 days before enrollment. - Patients with ANC<1.0 x10(9)/L within 14 days before enrollment. - Patients with peripheral neuropathy >/= grade 3 within 14 days before enrollment.", "gender": "All", "minimum_age": "17 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "PS-341", "mesh_term": ["Lymphoma", "Lymphoma, B-Cell", "Bortezomib", "Proteasome Inhibitors"], "id": "NCT00038571"}